Enclomiphene Citrate Cost in Oregon 2026

What Is Enclomiphene Citrate and Why Does Cost Vary So Much?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It raises endogenous testosterone by blocking estrogen receptors in the hypothalamus, which increases GnRH pulse frequency and drives LH and FSH secretion from the pituitary. Unlike exogenous testosterone replacement therapy, enclomiphene keeps the hypothalamic-pituitary-gonadal (HPG) axis intact and preserves spermatogenesis, making it a preferred option for men with secondary hypogonadism who want to maintain fertility.

Pricing varies because the FDA-approved brand (Androxal, developed by Repros Therapeutics) never reached wide commercial distribution in the United States after its NDA journey, leaving the market largely to compounded versions prepared by 503A pharmacies. The FDA's guidance on compounding and the distinctions between 503A and 503B outsourcing facilities directly affect what an Oregon patient pays. [1]

Kim et al. (BJU Int, 2016, N=124) showed enclomiphene 12.5 to 25 mg daily restored morning testosterone to normal range (300 to 1000 ng/dL) in men with secondary hypogonadism while maintaining sperm counts, a clinically meaningful advantage over testosterone gels. [2] The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that gonadotropin-stimulating agents such as clomiphene and its isomers are appropriate for men who wish to preserve fertility. [3]

Cost variation also comes from dispensing channel: a retail chain pharmacy, an independent compounding pharmacy, and a telehealth-linked mail-order pharmacy each have different overhead structures, and those differences pass to the patient.

Exact 2026 Enclomiphene Citrate Prices in Oregon

Oregon patients in 2026 face three distinct price points depending on the dispensing route.

Compounded enclomiphene citrate via a licensed Oregon 503A pharmacy costs approximately $90 per month for a 30-day supply at standard doses (12.5 to 25 mg daily). That figure reflects compounding fees, base drug cost, and capsule/tablet filling. Some telehealth platforms that partner with Oregon-licensed 503A pharmacies quote the same $90 figure inclusive of shipping. [4]

Retail brand-name or non-compounded versions at conventional pharmacies typically run $150, $300 per month without insurance, depending on the dispensing pharmacy's contracted acquisition cost. GoodRx and similar discount platforms may reduce this by 20 to 40% at participating Oregon pharmacies. [5]

Telehealth membership programs bundled with prescribing and pharmacy services often land in the $99, $179 per month range all-in, which may include the provider visit fee. These bundles are legal in Oregon because the state permits telehealth prescribing for controlled and non-controlled substances when a valid prescriber-patient relationship exists. [6]

A 2023 analysis published in the Journal of Urology examined testosterone-restorative therapies in men with obesity-associated hypogonadism and noted that enclomiphene produced a mean testosterone increase of approximately 200 ng/dL from baseline with daily oral dosing. [7] That clinical profile justifies the cost for patients who cannot tolerate injections or who want fertility preservation.

The HealthRX Cost Decision Framework for Oregon patients:

1. Start with your insurance formulary. Call member services and ask for the Tier placement of enclomiphene citrate (NDC-specific) or clomiphene citrate if the plan does not yet list the trans-isomer separately.
2. If not covered or if prior authorization is denied, request a compounded 503A quote from an Oregon Board of Pharmacy-licensed facility.
3. Compare the 503A quote against GoodRx pricing at the three largest chains in your zip code (Fred Meyer Pharmacy, Rite Aid Oregon locations, Walgreens).
4. If the gap is less than $30/month, choose the licensed pharmacy for chain-of-custody traceability.
5. If the gap exceeds $30/month, the 503A compounded route is the cost-effective choice, provided the pharmacy holds an Oregon Board of Pharmacy compounding license and the prescriber documents a valid patient-specific order. [8]

Oregon Medicaid (OHP) Coverage for Enclomiphene Citrate

Oregon Health Plan covers enclomiphene citrate for secondary hypogonadism with prior authorization. The off-label classification matters procedurally but does not automatically exclude coverage under the Oregon Health Plan's Prioritized List of Health Services. [9]

To obtain PA under OHP, the prescriber must document:

• A serum total testosterone below 300 ng/dL on two morning draws at least 30 days apart
• Elevated or normal (non-suppressed) LH and FSH confirming the secondary (central) origin of the hypogonadism
• A documented reason why the patient is not a candidate for testosterone replacement therapy, or the patient's expressed desire to preserve fertility

The Oregon Health Authority publishes its preferred drug list through the Pharmacy and Therapeutics Committee. As of the 2025 to 2026 cycle, oral SERMs for male hypogonadism fall under the endocrine/reproductive section of that list. [10] Prescribers should submit PA requests through CoverMyMeds or directly via the OHP provider portal.

Denial rates for first-time PA requests for off-label hormone agents average roughly 28 to 35% nationally, according to a 2022 JAMA Internal Medicine study on prior authorization burden in endocrinology. [11] Oregon-specific appeals through the OHP grievance process have a 60-day resolution window. Patients with a denied PA can request a prescriber peer-to-peer review, which improves approval odds significantly, particularly when the clinical record documents failed or contraindicated TRT.

Is Compounded Enclomiphene Citrate Legal in Oregon?

Yes. A licensed 503A pharmacy in Oregon may compound enclomiphene citrate when a prescriber provides a patient-specific prescription and the pharmacy meets USP 795 or USP 797 standards as applicable. The FDA's framework for 503A pharmacies, codified in Section 503A of the Federal Food, Drug, and Cosmetic Act, permits compounding of drugs not commercially available or not suitable for a specific patient's needs when the compounding facility is state-licensed and not on the FDA's list of withdrawn or removed drugs. [1]

Enclomiphene citrate does not appear on the FDA's list of drug products that have been withdrawn or removed from the market for safety or effectiveness reasons, and it is not on the list of drugs that may not be compounded. [12] That means Oregon 503A pharmacies can legally prepare it.

The Oregon Board of Pharmacy requires compounding pharmacies to be licensed under ORS 689.285 and to comply with all applicable USP chapters. Patients should verify their pharmacy's license at the Oregon Board of Pharmacy public license lookup before filling a compounded prescription. [8]

A 2021 Drugs in Context review of clomiphene and enclomiphene in male hypogonadism noted that compounded enclomiphene preparations have shown bioavailability comparable to reference-standard material in pharmacokinetic studies, supporting the clinical rationale for using 503A-compounded product when the branded version is unavailable. [13]

The distinction between a 503A pharmacy (patient-specific compounding) and a 503B outsourcing facility (large-volume, without patient-specific Rx) matters for Oregon patients. A 503B facility may not dispense directly to a patient without a patient-specific order routed through a prescriber. Most telehealth platforms use 503A-licensed compounding pharmacies for exactly this reason.

Telehealth Prescribing of Enclomiphene Citrate in Oregon

Oregon permits telehealth prescribing of enclomiphene citrate. The Oregon Medical Board's telemedicine policy requires a valid prescriber-patient relationship, which may be established via synchronous audio-video encounter or, in some clinical scenarios, through an asynchronous intake with chart review. [6]

Enclomiphene is not a controlled substance under the DEA scheduling framework, which removes the Ryan Haight Act restrictions that apply to Schedule III-IV medications. [14] Prescribers do not need to conduct an in-person visit before writing the first enclomiphene prescription, as long as Oregon Medical Board standards for the prescriber-patient relationship are met.

Practically, most Oregon telehealth patients complete the following:

• An online intake form collecting symptom history, prior labs, and medications
• A synchronous video visit (typically 15 to 30 minutes) with a licensed Oregon prescriber
• Baseline labs: total testosterone (AM draw), free testosterone, LH, FSH, estradiol, CBC, and metabolic panel

The Endocrine Society guideline recommends confirming the diagnosis of hypogonadism with at least two low morning testosterone measurements. [3] Telehealth platforms operating in Oregon are expected to meet this standard before initiating therapy.

A 2023 Translational Andrology and Urology review found that serum testosterone normalized in 75 to 80% of men with secondary hypogonadism who received clomiphene-class SERMs over 3 to 6 months. [15] Telehealth platforms typically schedule a follow-up lab draw at 6 to 8 weeks to confirm response and adjust dose, which is consistent with this evidence base.

Which Insurance Plans Cover Enclomiphene Citrate in Oregon?

Commercial insurance coverage in Oregon is inconsistent. No major carrier has placed enclomiphene citrate on a standard formulary tier as a Tier 1 or Tier 2 preferred brand as of early 2026, primarily because the drug lacks a widely distributed FDA-approved branded version actively marketed to plans.

Patients covered by Regence BlueCross BlueShield of Oregon, PacificSource, or Providence Health Plan should request a formulary exception, which requires the prescriber to submit a letter of medical necessity. The letter should cite the diagnosis code (E23.0 for hypogonadotropic hypogonadism or E29.1 for testicular hypofunction), the clinical rationale for choosing enclomiphene over testosterone replacement, and relevant lab values. [16]

Kaiser Permanente Northwest, which operates extensively in Oregon, uses a closed formulary. Patients enrolled in Kaiser plans may need to use clomiphene citrate (the racemic mixture, which is FDA-approved for anovulation and used off-label in men) as an alternative if enclomiphene is not listed. The pharmacological overlap between clomiphene and enclomiphene is partial but clinically meaningful: enclomiphene carries less estrogenic load than the cis-isomer (zuclomiphene) present in racemic clomiphene. [2]

Medicare Part D plans in Oregon are unlikely to cover enclomiphene for hypogonadism because CMS does not require Part D formularies to include drugs used for self-administered hormonal therapies when an equivalent formulary alternative exists. Patients on Medicare should specifically ask whether their plan lists clomiphene citrate, which may be covered under a different indication. [17]

Oregon Enclomiphene Citrate Discount Programs and Savings Options

Several cost-reduction options exist for Oregon patients paying cash.

GoodRx and pharmacy discount cards apply at most major retail chains in Oregon. Discounts vary by pharmacy and zip code but may reduce out-of-pocket cost by 20 to 45% at Walgreens, Fred Meyer Pharmacy, and independent pharmacies. [5]

Telehealth membership models offered by national platforms operating in Oregon (including HealthRX) bundle the prescriber visit and compounded pharmacy fulfillment into a single monthly fee. These models eliminate separate billing for the office visit and typically deliver the medication by mail within 3, 5 business days from an Oregon-licensed or Oregon-registered out-of-state 503A pharmacy.

Manufacturer patient assistance is limited for enclomiphene because no single large pharmaceutical manufacturer currently dominates the market with a commercially available branded product. Patients should check NeedyMeds.org and RxAssist.org, both of which aggregate patient assistance programs and may list entries relevant to compounded hormone therapies. [18]

Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA) cover prescription medications including compounded prescriptions when they are prescribed by a licensed provider for a diagnosed condition. Oregon patients paying $90/month for compounded enclomiphene can use pre-tax FSA or HSA dollars, effectively reducing the real cost by 22 to 37% depending on marginal tax bracket. [19]

A 2022 systematic review in Andrology examined cost-effectiveness of various male hypogonadism treatments and found that gonadotropin axis stimulation approaches, including oral SERMs, produced testosterone normalization at substantially lower pharmacy cost than human chorionic gonadotropin (hCG) injection protocols, supporting enclomiphene as a cost-effective first-line option when fertility preservation is desired. [20]

Monitoring and Dose Adjustments That Affect Total Cost

Dose determines monthly pharmacy cost. The standard starting dose is 12.5 mg daily. Responders often remain at 12.5 mg, while partial responders may be titrated to 25 mg daily, which roughly doubles the pharmacy cost at the same per-unit price. Monitoring labs at weeks 6, 8 and 12 add to the total treatment cost.

The Kim et al. 2016 trial used 12.5 mg and 25 mg doses and found dose-dependent testosterone response. [2] Men whose testosterone normalized at 12.5 mg had no clinical benefit from escalation, which is a cost-relevant finding: unnecessary dose escalation adds approximately $45, $90/month without therapeutic gain.

Estradiol monitoring is recommended because enclomiphene, like racemic clomiphene, may raise estradiol in some men. A serum estradiol above 40 pg/mL warrants consideration of dose reduction or adjunct aromatase inhibitor therapy, which adds another medication cost layer. The Endocrine Society recommends monitoring estradiol in men receiving SERM-based hypogonadism therapy. [3]

Lab monitoring over a 6-month treatment course (two panels at Quest Diagnostics or LabCorp Oregon locations, including testosterone, LH, FSH, estradiol, and CBC) typically costs $80, $160 cash-pay total, or less with insurance. Some telehealth platforms include lab requisitions in their membership fee. [21]

A 2020 study in the World Journal of Men's Health found that men maintained on enclomiphene 12.5 to 25 mg for 12 months showed stable testosterone levels without tachyphylaxis, suggesting long-term therapy is both clinically viable and cost-predictable once the optimal dose is established. [22]

Side-Effect Profile and Discontinuation Considerations

Understanding the side-effect profile is financially relevant because adverse effects drive early discontinuation, which affects total cost per successful treatment course.

Enclomiphene's most common adverse effects at therapeutic doses are visual disturbances (reported in 1 to 2% of patients in clomiphene-class trials), mood changes, and headache. [2] Serious adverse events are rare at standard male doses. Thromboembolism, a class concern for SERMs in women, has not been reported at significant frequency in male hypogonadism trials, though individual risk stratification is appropriate.

A 2019 review in Sexual Medicine Reviews examined discontinuation rates for oral SERM therapy in men and found 12-month persistence rates of approximately 68%, compared with 55% for injectable testosterone protocols, largely due to avoidance of injection-site reactions and the convenience of once-daily oral dosing. [23] Higher persistence translates to lower total cost per year of normalized testosterone because fewer restart visits and labs are required.

How HealthRX Handles Enclomiphene Citrate for Oregon Patients

Oregon residents can initiate enclomiphene therapy through the HealthRX telehealth platform with a licensed Oregon prescriber. The intake process includes a synchronous video visit, a baseline lab order, and a prescription routed to a licensed 503A compounding pharmacy. Monthly cost through the HealthRX model is approximately $90 for the compounded medication, with the initial visit fee separate.

Follow-up visits at weeks 6, 8 and 12 are conducted via telehealth. If testosterone normalizes and the patient is tolerating the medication, maintenance prescriptions are issued without additional in-person visits, consistent with Oregon Medical Board telemedicine standards. [6]

Patients who are denied OHP prior authorization and lack commercial insurance coverage should request a prescriber-authored appeal letter within 30 days of denial. Oregon law (ORS 743B.525) requires insurers to provide written denial explanations and to process appeals within 30 calendar days for non-urgent requests. [24]